MIRM
Mirum Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-28/100
Last price
79.16
▼ 2.28 (2.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
82.38
Prev close
81.43
Day high
81.94
Day low
77.78
Volume
1.15M
Market cap
$5.15B
P/E (TTM)
—
52W range
63.23 – 130.00
Day trading desk
Gap from prior close
+1.17%
Prior close 81.43
VWAP
79.37
-0.28% from price
Relative volume
1.34×
Normal
Session range
5.92%
77.78 – 82.38
Position in range
30%
Near session low
ATR (14D)
3.66
4.62% of price
Prior day high
83.35
PDH
Prior day low
81.23
PDL
Bid / ask spread
—
Quote not published
Session volume
922.54K
Avg 689.47K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.47%
-11.4%
1M
-21.46%
-22.6%
3M
-38.36%
-42.9%
6M
-17.15%
-35.3%
YTD
+0.33%
-13.9%
1Y
+8.64%
-7.8%
3Y
+150.79%
+68.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MIRM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.89K
Net buying
Buy transactions
14
197.62K shares
Sell transactions
16
181.73K shares
Net transactions
+30
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
840.87K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | BJERKHOLT ERIC H Chief Financial Officer |
SELL | 9.94K | $978.09K | Direct |
| Sep 11, 26 | BJERKHOLT ERIC H Chief Financial Officer |
— | 18.33K | — | Direct |
| Sep 2, 26 | HOWE JOLANDA MARIE Officer |
SELL | 658 | $65.80K | Direct |
| Sep 1, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
SELL | 30.00K | $2.96M | Direct |
| Sep 1, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
CONVERSION | 30.00K | $88.08K | Direct |
| Aug 18, 26 | HOWE JOLANDA MARIE Officer |
SELL | 40.00K | $4.00M | Direct |
| Aug 18, 26 | HOWE JOLANDA MARIE Officer |
CONVERSION | 40.00K | $250.80K | Direct |
| Aug 11, 26 | BJERKHOLT ERIC H Chief Financial Officer |
SELL | 6.00K | $599.51K | Direct |
| Aug 10, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
SELL | 20.00K | $1.98M | Direct |
| Aug 10, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
CONVERSION | 20.00K | $58.72K | Direct |
| Aug 3, 26 | HOWE JOLANDA MARIE Officer |
SELL | 1.84K | $193.73K | Direct |
| Jul 6, 26 | BJERKHOLT ERIC H Chief Financial Officer |
SELL | 5.00K | $611.27K | Direct |
| Jul 6, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
SELL | 20.00K | $2.45M | Direct |
| Jul 6, 26 | PEETZ CHRISTOPHER Chief Executive Officer |
CONVERSION | 20.00K | $58.72K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BJERKHOLT ERIC H |
Chief Financial Officer | 44.74K | Sale |
BREGE LAURA A |
Director | 15.70K | Sale |
CARDON LON PH.D. |
Director | 9.68K | Conversion of Exercise of derivative security |
FISCHER LAURENT D M.D. |
Director | 10.73K | Conversion of Exercise of derivative security |
GREY MICHAEL G. |
Director | 280.16K | Sale |
HERON PATRICK J |
Director | — | Purchase |
PEETZ CHRISTOPHER |
Chief Executive Officer | 381.94K | Sale |
QUAN JOANNE |
Officer | 18.86K | Sale |
RADOVICH PETER |
President | 57.26K | Conversion of Exercise of derivative security |
WALBERT TIMOTHY P |
Director | 9.68K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$5.15B
Enterprise value$5.47B
Revenue (TTM)$618.07M
Gross profit$505.11M
EBITDA$-70.28M
Net income$-860.21M
EPS (TTM)$-13.72
Free cash flow$76.62M
Total cash$438.29M
Total debt$762.95M
Book value / share$-0.16
Shares outstanding64.93M
Float56.42M
Short % of float12.45%
Dividend yield0.00%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E—
Forward P/E-228.60
PEG ratio—
Price / sales—
Price / book—
EV / revenue8.85
EV / EBITDA-77.84
Gross margin81.73%
Operating margin-14.81%
Profit margin-139.18%
Return on equity-702.97%
Return on assets-6.79%
Debt / equity—
Current ratio2.86
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $521.31M | $336.89M | $186.37M | $77.06M | +54.7% |
| Operating revenue | $521.31M | $336.89M | $186.37M | $77.06M | +54.7% |
| Cost of revenue | $100.24M | $81.64M | $47.04M | $12.37M | +22.8% |
| Gross profit | $421.07M | $255.25M | $139.34M | $64.69M | +65.0% |
| Research & development | $186.18M | $140.63M | $102.61M | $106.84M | +32.4% |
| Selling, general & admin | $257.03M | $202.22M | $145.88M | $89.07M | +27.1% |
| Total operating expense | $443.21M | $342.85M | $248.49M | $195.91M | +29.3% |
| Operating income | -$22.14M | -$87.61M | -$109.15M | -$131.22M | +74.7% |
| Net interest income | -$1.66M | -$519.00K | -$1.37M | -$12.12M | -220.2% |
| Pre-tax income | -$21.43M | -$86.91M | -$162.42M | -$142.07M | +75.3% |
| Tax provision | $1.94M | $1.03M | $991.00K | -$6.41M | +88.0% |
| Net income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | +73.4% |
| Net income to common | -$23.36M | -$87.94M | -$163.41M | -$135.66M | +73.4% |
| Basic EPS | -0.47 | -1.85 | -3.94 | -4.01 | +74.6% |
| Diluted EPS | -0.47 | -1.85 | -3.94 | -4.02 | +74.6% |
| EBIT | -$7.04M | -$72.60M | -$147.32M | -$126.09M | +90.3% |
| EBITDA | $17.21M | -$48.97M | -$136.49M | -$122.85M | +135.1% |
| Basic shares | 50.20M | 47.52M | 40.89M | 33.84M | +5.6% |
| Diluted shares | 50.20M | 47.52M | 40.89M | 33.98M | +5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $296.68M | $222.50M | $286.33M | $28.00M | +33.3% |
| Cash & short-term investments | $383.33M | $280.31M | $286.33M | $151.72M | +36.7% |
| Accounts receivable | $123.33M | $78.29M | $67.97M | $23.99M | +57.5% |
| Inventory | $24.89M | $22.40M | $22.31M | $5.57M | +11.1% |
| Total current assets | $549.68M | $392.79M | $387.54M | $190.22M | +39.9% |
| Property, plant & equipment | $10.60M | $9.81M | $1.99M | $2.35M | +8.0% |
| Goodwill & intangibles | $260.92M | $249.82M | $252.93M | $58.95M | +4.4% |
| Total assets | $842.81M | $670.75M | $646.62M | $352.91M | +25.7% |
| Total current liabilities | $205.80M | $126.55M | $87.06M | $64.73M | +62.6% |
| Long-term debt | $309.80M | $308.08M | $306.42M | — | +0.6% |
| Total debt | $319.45M | $317.76M | $308.14M | $2.19M | +0.5% |
| Total liabilities | $528.12M | $445.11M | $397.95M | $210.87M | +18.6% |
| Retained earnings | -$667.54M | -$644.18M | -$556.24M | -$392.82M | -3.6% |
| Shareholder equity | $314.69M | $225.64M | $248.67M | $142.04M | +39.5% |
| Working capital | $343.88M | $266.24M | $300.48M | $125.50M | +29.2% |
| Net tangible assets | $53.77M | -$24.18M | -$4.25M | $83.08M | +322.4% |
| Shares issued | 51.90M | 48.34M | 46.72M | 36.96M | +7.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | — | +73.4% |
| Depreciation & amortisation | $24.24M | $23.63M | $10.83M | $3.24M | — | +2.6% |
| Stock-based compensation | $71.42M | $48.44M | $35.02M | $27.01M | — | +47.4% |
| Change in working capital | -$19.71M | $22.59M | -$19.22M | -$21.05M | — | -187.3% |
| Operating cash flow | $55.83M | $10.32M | -$70.94M | -$120.14M | — | +440.7% |
| Capital expenditure | -$954.00K | -$20.99M | -$20.11M | -$278.00K | — | +95.5% |
| Investing cash flow | -$23.95M | -$90.13M | -$107.20M | $7.70M | — | +73.4% |
| Dividends paid | — | — | — | — | $0 | — |
| Financing cash flow | $40.14M | $17.70M | $336.60M | $109.09M | — | +126.8% |
| Free cash flow | $54.87M | -$10.67M | -$91.05M | -$120.41M | — | +614.4% |
| End cash position | $298.17M | $222.93M | $286.33M | $128.00M | — | +33.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $176.24M | $159.88M | $148.93M | $133.01M | $127.78M | +10.2% |
| Operating revenue | $176.24M | $159.88M | $148.93M | $133.01M | $127.78M | +10.2% |
| Cost of revenue | $30.35M | $28.80M | $28.26M | $25.54M | $23.42M | +5.4% |
| Gross profit | $145.90M | $131.08M | $120.67M | $107.47M | $104.36M | +11.3% |
| Research & development | $90.53M | $97.91M | $51.11M | $42.96M | $46.07M | -7.5% |
| Selling, general & admin | $81.47M | $96.33M | $74.13M | $61.91M | $63.29M | -15.4% |
| Total operating expense | $172.00M | $194.24M | $125.23M | $104.87M | $109.35M | -11.5% |
| Operating income | -$26.10M | -$63.16M | -$4.57M | $2.60M | -$4.99M | +58.7% |
| Net interest income | $1.23M | -$215.00K | -$178.00K | -$355.00K | -$556.00K | +673.5% |
| Pre-tax income | -$65.54M | -$789.68M | -$4.96M | $2.64M | -$5.46M | +91.7% |
| Tax provision | $1.69M | $475.00K | $767.00K | -$262.00K | $402.00K | +255.6% |
| Net income | -$67.23M | -$790.15M | -$5.73M | $2.90M | -$5.86M | +91.5% |
| Net income to common | -$67.23M | -$790.15M | -$5.73M | $2.90M | -$5.86M | +91.5% |
| Basic EPS | -1.06 | -13.43 | -0.11 | 0.06 | -0.12 | +92.1% |
| Diluted EPS | -1.06 | -13.43 | -0.11 | 0.05 | -0.12 | +92.1% |
| EBIT | -$62.92M | -$786.06M | -$1.36M | $6.25M | -$1.87M | +92.0% |
| EBITDA | -$55.98M | -$779.19M | $4.71M | $12.31M | $4.19M | +92.8% |
| Basic shares | 63.37M | 58.85M | 51.90M | 50.64M | 49.73M | +7.7% |
| Diluted shares | 63.37M | 58.85M | 51.90M | 56.99M | 49.73M | +7.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $330.73M | $324.91M | $296.68M | $282.02M | $228.12M | +1.8% |
| Cash & short-term investments | $438.29M | $386.26M | $383.33M | $375.55M | $304.55M | +13.5% |
| Accounts receivable | $145.36M | $133.11M | $123.33M | $107.13M | $106.84M | +9.2% |
| Inventory | $25.77M | $25.52M | $24.89M | $24.02M | $22.94M | +1.0% |
| Total current assets | $636.31M | $569.44M | $549.68M | $530.58M | $453.40M | +11.7% |
| Property, plant & equipment | $14.28M | $15.06M | $10.60M | $9.78M | $10.12M | -5.2% |
| Goodwill & intangibles | $247.39M | $254.15M | $260.92M | $231.90M | $237.87M | -2.7% |
| Total assets | $1.04B | $890.92M | $842.81M | $785.12M | $725.83M | +17.3% |
| Total current liabilities | $222.79M | $272.82M | $205.80M | $160.36M | $144.80M | -18.3% |
| Long-term debt | $750.08M | $310.25M | $309.80M | $309.37M | $308.93M | +141.8% |
| Total debt | $762.95M | $323.78M | $319.45M | $318.76M | $318.90M | +135.6% |
| Total liabilities | $1.06B | $648.42M | $528.12M | $493.07M | $470.67M | +62.8% |
| Retained earnings | -$1.52B | -$1.46B | -$667.54M | -$661.81M | -$664.72M | -4.6% |
| Shareholder equity | -$10.42M | $242.49M | $314.69M | $292.05M | $255.16M | -104.3% |
| Working capital | $413.52M | $296.61M | $343.88M | $370.22M | $308.60M | +39.4% |
| Net tangible assets | -$257.81M | -$11.66M | $53.77M | $60.15M | $17.29M | -2,111.1% |
| Shares issued | 64.75M | 60.93M | 51.90M | 51.31M | 50.06M | +6.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$67.23M | -$790.15M | -$5.73M | $2.90M | -$5.86M | +91.5% |
| Depreciation & amortisation | $6.94M | $6.87M | $6.07M | $6.06M | $6.06M | +0.9% |
| Stock-based compensation | $30.57M | $36.20M | $19.03M | $18.13M | $18.47M | -15.5% |
| Change in working capital | -$40.22M | $102.22M | -$14.01M | $12.14M | -$6.56M | -139.3% |
| Operating cash flow | -$44.25M | -$228.76M | $6.07M | $39.68M | $12.04M | +80.7% |
| Capital expenditure | -$25.02M | -$10.66M | -$600.00K | -$187.00K | -$126.00K | -134.6% |
| Investing cash flow | -$159.99M | -$11.57M | $1.01M | -$2.23M | -$6.60M | -1,282.9% |
| Financing cash flow | $211.44M | $270.08M | $9.00M | $16.10M | $8.69M | -21.7% |
| Free cash flow | -$69.28M | -$239.43M | $5.47M | $39.49M | $11.91M | +71.1% |
| End cash position | $332.46M | $326.64M | $298.17M | $282.50M | $228.60M | +1.8% |
Options analytics
Put / call volume
3.31
Put-heavy session
Put / call open interest
0.85
Positioning, not flow
Max pain
105.00
+32.5% from spot
ATM implied vol
99.3%
Nearest strike to spot
Skew (10% OTM)
+16.8%
Puts bid over calls
Call volume
49
Contracts, this expiry
Put volume
162
Contracts, this expiry
Heaviest call OI
105.00
75 contracts
Heaviest put OI
90.00
74 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.75 | -0.80 | -7.4% |
| Mar 2026 | -0.36 | -1.09 | -205.6% |
| Dec 2025 | 0.06 | -0.12 | -308.7% |
| Sep 2025 | -0.16 | 0.05 | +131.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.43 | 2 | $177.79M | +33.7% |
| Next quarter | -0.61 | 2 | $183.25M | +23.0% |
| Current year | -15.14 | 1 | $696.55M | +33.6% |
| Next year | -0.35 | 3 | $819.52M | +17.7% |
Analyst targets & ownership
Mean target$145.79
High target$195.00
Low target$118.00
Implied upside84.18%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy4 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders1.29%
Held by institutions111.77%
Institutions holding442
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
85.69
-7.63% from price
SMA 20
90.80
-12.72% from price
SMA 50
96.87
-18.19% from price
SMA 100
102.78
-22.99% from price
SMA 200
98.38
-19.44% from price
EMA 12
86.24
-8.22% from price
EMA 26
91.03
-13.05% from price
EMA 50
95.74
-17.32% from price
RSI (14)
21.8
Oversold
MACD (12,26,9)
-4.79
Hist -0.95
ATR (14)
3.66
4.62% of price
Realised vol 30D
32.5%
Annualised
Bollinger upper
103.02
20, 2σ
Bollinger lower
78.59
20, 2σ
50 / 200 cross
Death
96.87 vs 98.38
Trend bias
Below 200
-19.44%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.96
Less volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
32.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-38.4%
Peak to trough
Max drawdown 5Y
-40.3%
Peak to trough
ATR 14
3.66
4.62% of price
Beta (reported)
0.62
5Y monthly, from filing
Short interest
Shares short
6.28M
Prior 6.49M
Change vs prior
-3.2%
Shorts covering
% of float
12.45%
Elevated
% of shares out
9.67%
Against total outstanding
Days to cover
12.5
Crowded exit
Float
56.42M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Sep 29, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Sep 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 6, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 2, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jun 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jun 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-08
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-18
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-27
Headlines
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
MarketBeat · 4d ago
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
BioPharma Dive · 7d ago
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
Zacks · 8d ago
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data?
Simply Wall St. · 8d ago
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Zacks · 9d ago
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
Benzinga · 9d ago
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Business Wire · 9d ago
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Stocktwits · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.